Histologic grade is a better predictor of specific survival than Ki67 in localized ER+/HER2-breast cancer: a real-world study

被引：0
|
作者：
Sanchez, Cesar
Alejandro, Cataldo
Walbaum, Benjamin
Acevedo, Francisco
Constabel, Christine
Saure, Antoine
Rey, Pablo
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-18-02
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Using real-world data to evaluate the performance of endocrine therapies in ER+/Her2-metastatic breast cancer patients.
    Chen, Tenghui
    Zhang, Zhaojie
    Gao, Lei
    Scholz, Catherine
    Gualberto, Antonio
    Yu, Lihua
    Yu, Kun
    CANCER RESEARCH, 2022, 82 (12)
  • [32] Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2− breast cancers by the 2015 St. Gallen consensus classification
    Yue Hu
    Ran Gu
    Jinghua Zhao
    Yaping Yang
    Fengtao Liu
    Liang Jin
    Kai Chen
    Haixia Jia
    Hongli Wang
    Qiang Liu
    Fengxi Su
    Weijuan Jia
    BMC Cancer, 17
  • [33] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER, part 1)
    Spring, Laura M.
    Scarpetti, Lauren
    Niemierko, Andrzej
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth A.
    Smith, Elisabeth
    Abraham, Elizabeth
    Shin, Jennifer
    Patel, Jaymin M.
    Comander, Amy
    Mulvey, Therese
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [34] Assessment of high Ki67 (≥20%) ER+HER2-breast cancer with a 21-gene multigene assay
    Ahn, S. G.
    Bae, S. J.
    Jang, J. S.
    Jeong, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S608 - S608
  • [35] AI-based intra-tumor heterogeneity score of Ki67 expression as a prognostic marker for early-stage ER+/HER2- breast cancer
    Lu, Wenqi
    Lashen, Ayat G.
    Wahab, Noorul
    Miligy, Islam M.
    Jahanifar, Mostafa
    Toss, Michael
    Graham, Simon
    Bilal, Mohsin
    Bhalerao, Abhir
    Atallah, Nehal M.
    Makhlouf, Shorouk
    Ibrahim, Asmaa Y.
    Snead, David
    Minhas, Fayyaz
    Raza, Shan E. Ahmed
    Rakha, Emad
    Rajpoot, Nasir
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2024, 10 (01):
  • [36] Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
    Abubakar, Mustapha
    Figueroa, Jonine
    Ali, H. Raza
    Blows, Fiona
    Lissowska, Jolanta
    Caldas, Carlos
    Easton, Douglas F.
    Sherman, Mark E.
    Garcia-Closas, Montserrat
    Dowsett, Mitch
    Pharoah, Paul D.
    MODERN PATHOLOGY, 2019, 32 (09) : 1244 - 1256
  • [37] Validation of the 'APIS Breast Cancer Subtyping Kit' mRNA assay to test for ER, PR, HER-2, and Ki67 in Invasive Breast Cancer
    Simonovic, A., V
    Collins, N.
    Costa, D.
    Faulkes, C.
    Kobutungi, B.
    Kolio, P.
    Paterson, F.
    Horsnell, J.
    Pakzad, F.
    Irvine, T.
    Partlett, P.
    Clayton, E.
    Di Palma, S.
    JOURNAL OF PATHOLOGY, 2024, 264 : S21 - S21
  • [38] Comparison of risk assessment in primary ER+, HER2-Breast Cancer in a real-world data set: Classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
    Jank, Paul
    Denkert, Carsten
    Lindner, Judith L.
    Lehmann, Annika
    Pfitzner, Berit M.
    Blohmer, Jens-Uwe
    Horst, David
    Kronenwett, Ralf
    Schmitt, Wolfgang D.
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy
    Barbieri, E.
    Piacentini, F.
    Dieci, M. V.
    Ficarra, G.
    Conte, P. F.
    Guarneri, V.
    CANCER RESEARCH, 2010, 70
  • [40] A real-world evidence study of BRCA mutations and survival in HER2-negative breast cancer
    Dalvi, Tapashi
    McLaurin, Kimmie
    Briceno, Josefa
    Nordstrom, Beth
    Bennett, James
    Hettle, Robert
    Murphy, Brian
    Collins, Jenna
    McCutcheon, Susan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 72 - 72
12345